Starling Oncology (STLNW) Shares Outstanding (2019 - 2026)

Starling Oncology (STLNW) has reported Shares Outstanding (Entity) for 8 consecutive years, with $100.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Shares Outstanding (Entity) rose 7.71% year-over-year to $100.5 million; the trailing twelve-month figure through Jun 2026 stood at $100.5 million (up 7.71% YoY), and the FY2025 full-year result was $98.9 million, up 30.53% from the prior year.
• Shares Outstanding (Entity) steadied at $100.5 million in Q2 2026 per STLNW's latest filing, from $100.0 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $100.5 million in Q2 2026 and bottomed at $72.0 million in Q2 2022.
• Historically, Shares Outstanding (Entity) has averaged $81.4 million across 5 years, with a median of $74.9 million in 2024.
• The widest YoY moves for Shares Outstanding (Entity): up 218.59% in 2022, down 0.02% in 2022.
• Over 5 years, Shares Outstanding (Entity) stood at $73.3 million in 2022, then rose by 1.2% to $74.1 million in 2023, then increased by 2.15% to $75.7 million in 2024, then jumped by 30.53% to $98.9 million in 2025, then climbed by 1.62% to $100.5 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $100.5 million, $100.0 million, and $98.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.